Literature DB >> 31758410

Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET/CT.

Ariana Nodoushani1, Mohammed Samir El-Sady2, Mi-Ae Park2, Gloria L Castilloveitia3, Rodney H Falk4, Marcelo F Di Carli2, Marie Foley Kijewski2, Sharmila Dorbala2,4.   

Abstract

BACKGROUND: 18F-florbetapir PET is emerging as an excellent quantitative tool to quantify cardiac light chain (AL) amyloidosis burden. The primary aim of this study was to determine interobserver reproducibility and intraobserver repeatability, defined per the recommendations of the Quantitative Imaging Biomarker Alliance technical performance group, of PET 18F-florbetapir retention index (RI) in patients with cardiac AL amyloidosis.
METHODS: The study cohort comprised 37 subjects with systemic AL amyloidosis enrolled in the prospective study: Molecular Imaging of Primary Amyloid Cardiomyopathy (clinical trials.gov NCT: 02641145). Using 10 mCi of 18F-florbetapir, a 60-minute dynamic cardiac scan was acquired. Global and segmental left ventricular estimates of retention index (RI) of 18F-florbetapir were calculated (Carimas 2.9 software, Turku, Finland). RI was analyzed twice, at least 24 hours apart, by two independent observers. Intraobserver repeatability and interobserver reproducibility were evaluated using Bland-Altman plots and scatter plots with fitted linear regression curves.
RESULTS: All reproducibility (interobserver, r = 0.98) and repeatability (intraobserver, R=0.99 for each observer) measures of 18F-florbetapir RI are excellent. On the Bland-Altman plots, the agreement limits for global 18F-florbetapir RI were high and ranged for reproducibility (interobserver) from - 9.3 to + 9.4% (Fig. 1), and for repeatability (observer 1 from - 10.8 to + 10.7% and from - 9.2 to + 11.4%, for observer 2).
CONCLUSIONS: The present study showed excellent interobserver reproducibility and intraobserver repeatability of 18F-florbetapir PET retention index in patients with cardiac AL amyloidosis.
© 2019. American Society of Nuclear Cardiology.

Entities:  

Keywords:  PET; amyloid heart disease; heart failure; image analysis

Mesh:

Substances:

Year:  2019        PMID: 31758410      PMCID: PMC9513526          DOI: 10.1007/s12350-019-01961-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   3.872


  11 in total

Review 1.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Authors:  Rodney H Falk; Kevin M Alexander; Ronglih Liao; Sharmila Dorbala
Journal:  J Am Coll Cardiol       Date:  2016-09-20       Impact factor: 24.094

2.  Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software.

Authors:  Tanja Kero; Lars Lindsjö; Jens Sörensen; Mark Lubberink
Journal:  J Nucl Cardiol       Date:  2015-07-15       Impact factor: 5.952

3.  Imaging cardiac amyloidosis: an opportunity for nuclear cardiology.

Authors:  Sharmila Dorbala
Journal:  J Nucl Cardiol       Date:  2014-12       Impact factor: 5.952

4.  C-11 acetate has excellent reproducibility for quantification of myocardial oxidative metabolism.

Authors:  Sergey V Nesterov; Olli Turta; Chunlei Han; Maija Mäki; Irina Lisinen; Helena Tuunanen; Juhani Knuuti
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-12-22       Impact factor: 6.875

5.  Quantitative molecular imaging of cardiac amyloidosis: The journey has begun.

Authors:  Sharmila Dorbala; Marie Foley Kijewski; Mi-Ae Park
Journal:  J Nucl Cardiol       Date:  2015-07-16       Impact factor: 5.952

6.  Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.

Authors:  Sharmila Dorbala; Divya Vangala; James Semer; Christopher Strader; John R Bruyere; Marcelo F Di Carli; Stephen C Moore; Rodney H Falk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-20       Impact factor: 9.236

7.  First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Authors:  Morie A Gertz; Heather Landau; Raymond L Comenzo; David Seldin; Brendan Weiss; Jeffrey Zonder; Giampaolo Merlini; Stefan Schönland; Jackie Walling; Gene G Kinney; Martin Koller; Dale B Schenk; Spencer D Guthrie; Michaela Liedtke
Journal:  J Clin Oncol       Date:  2016-02-08       Impact factor: 44.544

8.  18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Authors:  Mi-Ae Park; Robert F Padera; Anthony Belanger; Shipra Dubey; David H Hwang; Vikas Veeranna; Rodney H Falk; Marcelo F Di Carli; Sharmila Dorbala
Journal:  Circ Cardiovasc Imaging       Date:  2015-08       Impact factor: 7.792

Review 9.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

10.  Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.

Authors:  Duncan B Richards; Louise M Cookson; Alienor C Berges; Sharon V Barton; Thirusha Lane; James M Ritter; Marianna Fontana; James C Moon; Massimo Pinzani; Julian D Gillmore; Philip N Hawkins; Mark B Pepys
Journal:  N Engl J Med       Date:  2015-07-15       Impact factor: 91.245

View more
  6 in total

1.  Nuclear Cardiology, the Future is Now!

Authors:  Rob Beanlands
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

2.  Editorial: 18F-Fluoride PET/MR in cardiac amyloid; simple addition versus synergy?

Authors:  Sarah A M Cuddy
Journal:  J Nucl Cardiol       Date:  2020-11-17       Impact factor: 5.952

Review 3.  Comprehensive approach to cardiac amyloidosis care: considerations in starting an amyloidosis program.

Authors:  Brett W Sperry; Julie A Khoury; Shahzad Raza; Julie L Rosenthal
Journal:  Heart Fail Rev       Date:  2021-08-30       Impact factor: 4.654

4.  What is the optimal cardiac screening for asymptomatic transthyretin gene mutation carriers?

Authors:  Sang-Geon Cho; Hyung Yoon Kim; Hee-Seung Bom
Journal:  J Nucl Cardiol       Date:  2019-11-25       Impact factor: 5.952

5.  Cases from a busy nuclear cardiology laboratory: Potential pitfalls in the interpretation of cardiac scintigraphy for ATTR cardiac amyloidosis.

Authors:  Ramsey M Wehbe; Preeti Kansal; Thomas A Holly
Journal:  J Nucl Cardiol       Date:  2020-05-07       Impact factor: 5.952

6.  Technetium-99m-3,3-diphosphono-1,2-2 propanodicarboxylic acid (DPD) in AL cardiac amyloidosis.

Authors:  Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2020-05-07       Impact factor: 5.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.